Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Published:2017-01 Issue:1 Volume:28 Page:184
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Deenen M.J.,Meulendijks D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/1/184/10296986/mdw533.pdf

Reference5 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

2. Safety of capecitabine: a review;Mikhail;Expert Opin Drug Saf,2010

3. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil;van Kuilenburg;Eur J Cancer,2004

4. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data;Meulendijks;Lancet Oncol,2015

5. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis;Deenen;J Clin Oncol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK;Personalized Medicine;2023-07

2. Transgelin-2 interacts with CD44 to regulate Notch1 signaling pathway and participates in colorectal cancer proliferation and migration;Journal of Physiology and Biochemistry;2021-09-23

3. Precision treatment in colorectal cancer: Now and the future;JGH Open;2019-02-08

4. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients;The Pharmacogenomics Journal;2019-02-06

5. The use of pharmacogenetics to increase the safety of colorectal cancer patients treatedwith fluoropyrimidines;Cancer Drug Resistance;2019